Dr. Dan Vogl

Hematology
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
Offers Telehealth
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dan Vogl is a Hematologist in Philadelphia, Pennsylvania. Dr. Vogl is rated as an Experienced provider by MediFind in the treatment of Pemphigus Vulgaris. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vogl is currently accepting new patients.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
NewYork-Presbyterian / Weill Cornell Medical Center
Residency
NewYork-Presbyterian/Columbia University Medical Center
Specialties
Hematology
Licenses
Internal Medicine in PA
Board Certifications
Hematology, 2008
Fellowships
Hospital of the University of Pennsylvania
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Penn Presbyterian Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Vogl has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Multiple Myeloma
Waldenstrom Macroglobulinemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma
Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma
Enrollment Status: Terminated
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Tasquinimod, Ixazomib, Lenalidomide, and Dexamethasone Chemotherapy
Study Phase: Phase 1
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 26, 2022
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Biological
Study Drug: CAR2 Anti-CD38 A2 CAR-T Cells
Study Phase: Phase 1
View 6 Less Clinical Trials

94 Total Publications

Outcomes of relapse after teclistamab therapy in multiple myeloma.
Outcomes of relapse after teclistamab therapy in multiple myeloma.
Journal: Blood cancer journal
Published: August 14, 2025
Similar Doctors
Experienced in Pemphigus Vulgaris
Dr. Daniel J. Lebovic
Hematology Oncology | Hematology | Oncology
Experienced in Pemphigus Vulgaris
Dr. Daniel J. Lebovic
Hematology Oncology | Hematology | Oncology

Alliance Cancer Specialists P.C.

1203 Langhorne Newtown Rd, Suite 135, 
Langhorne, PA 
 (22.6 miles away)
215-750-5050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Lebovic is a Hematologist Oncology specialist and a Hematologist in Langhorne, Pennsylvania. Dr. Lebovic is rated as a Distinguished provider by MediFind in the treatment of Pemphigus Vulgaris. His top areas of expertise are Colorectal Cancer, Childhood Iron Deficiency Anemia, Familial Colorectal Cancer, Bone Marrow Aspiration, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vogl's expertise for a condition
ConditionClose
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile